BOSTON, Oct. 11, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. ELTX “Elicio Therapeutics” or “Elicio”))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will present updated preliminary data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset,…Read More
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancers SITC 2023 Annual Meeting Elicio Therapeutics NASDAQELTX
